Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternative dosing schedules for irinotecan

M L Rothenberg1, J G Kuhn, L J Schaaf

  • 1Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Oncology (Williston Park, N.Y.)
|September 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Cancer chemotherapy and pharmacology·2014
Same author

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012

Exploring novel irinotecan (CPT-11) dosing, including every-2-week and daily oral schedules, may enhance antitumor activity and patient convenience. These strategies could improve integration into combination therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Irinotecan (CPT-11) is commonly administered weekly or every three weeks.
  • New routes and schedules for irinotecan administration are being investigated.

Purpose of the Study:

  • To explore alternative irinotecan dosing schedules, including every-2-week and daily oral administration.
  • To assess the potential for increased dose frequency and intensity with novel irinotecan regimens.
  • To evaluate the theoretical advantages of oral irinotecan administration.

Main Methods:

  • Phase I trials have investigated an every-2-week irinotecan schedule.
  • Phase I trials have explored daily oral irinotecan administration over 2 weeks out of 3.
  • Phase II trials are evaluating irinotecan in recurrent colorectal cancer with novel schedules.

Related Experiment Videos

Main Results:

  • Data suggest repeated smaller doses of topoisomerase I inhibitors may offer greater antitumor activity than intermittent large doses.
  • Oral administration offers theoretical benefits including enhanced conversion to active SN-38 and improved patient convenience.
  • Alternative schedules may allow for better integration into combination chemotherapy and combined-modality treatments.

Conclusions:

  • Novel irinotecan dosing schedules, such as every-2-week and oral administration, show promise for enhanced efficacy and convenience.
  • These alternative strategies may broaden the application of irinotecan in cancer treatment regimens.
  • Further research and clinical trials are warranted to fully establish the benefits of these new irinotecan administration methods.